Key strengths include a focused and differentiated oncology pipeline, particularly OST-HER2 in osteosarcoma, supported by encouraging clinical data and multiple favorable FDA designations. The proprietary tADC platform offers additional strategic depth and potential for future candidates or partnerships. Financially, the balance sheet has been significantly de-risked through the elimination of debt and a rebuild of cash, restoring positive equity and improving short-term liquidity. Taken together, OS Therapies combines a cleaner capital structure with a science-driven story targeting meaningful unmet medical needs.

Major risks stem from the early-stage, binary nature of the business model. The company has no revenue, widening accounting losses, and persistently negative free cash flow, making it dependent on continued access to external capital. Clinical and regulatory uncertainty is high: setbacks in OST-HER2 or delays in the tADC program would materially affect the company’s prospects. Even if OST-HER2 is approved, OS Therapies must still execute on commercialization or partnering in competitive oncology markets dominated by much larger players, and shareholders face ongoing dilution risk as additional funding is raised.

Looking forward, the company’s trajectory will be defined far more by scientific and regulatory milestones than by current financial metrics. Success in securing approval for OST-HER2 in osteosarcoma and advancing into broader HER2-positive indications could transform the revenue picture over time, while initial human data from tADC candidates would test the value of its second platform. In the near to medium term, investors should expect continued losses and cash burn, punctuated by potentially significant value inflection points around trial results, regulatory submissions, and strategic transactions. The opportunity is substantial but tightly linked to a small number of high-impact outcomes, and uncertainty remains high.